- VGXI and Cryoport announce a strategic partnership to support the development of cell and gene therapies and mRNA-based treatments.
- Partnership will provide biostorage and bioservices for plasmid DNA products, starting October 2024.
VGXI, Inc., a contract developer and manufacturer of nucleic acid biopharmaceuticals has announced a strategic partnership with Cryoport, Inc., a global provider in life sciences supply chain solutions. The collaboration aims to support biopharmaceutical companies in developing advanced therapies, including gene therapies, mRNA-based treatments, and DNA vaccines.
As part of this partnership, Cryoport will provide biostorage and bioservices from its Houston, Texas, facility. This will support plasmid DNA products manufactured at VGXI’s facilities in The Woodlands and Conroe, Texas. Operations under this partnership are expected to begin in October 2024. The partnership combines VGXI’s expertise in plasmid DNA manufacturing with Cryoport’s supply chain solutions, including shipping services and data support, ensuring a seamless delivery process for customers.
Jerrell Shelton, CEO of Cryoport, commented, “Being chosen by VGXI as a partner for biostorage and bioservices underscores our shared commitment to quality and innovation.”
This partnership is expected to enhance VGXI’s ability to deliver critical materials for gene therapies and clinical trials, providing a fully integrated solution that supports the clinical programs of biopharmaceutical companies.
Overview of outsourcing trends 
